A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

开始日期2025-05-01

申办/合作机构

Eli Lilly & Co.

NCT06824051

/ Active, not recruiting临床1期

A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

开始日期2025-02-17

申办/合作机构

Eli Lilly & Co.

CTIS2024-515905-25-00

/ Recruiting临床3期

J5P-MC-GZRA: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA); J5P-MC-GZ01: Participants with OSA unable or unwilling to use PAP therapy; J5P-MC-GZ02: Participants with OSA on PAP therapy - J5P-MC-GZRA

开始日期2025-02-03

申办/合作机构

Eli Lilly & Co.

100 项与 Orforglipron 相关的临床结果

登录后查看更多信息

100 项与 Orforglipron 相关的转化医学

登录后查看更多信息

100 项与 Orforglipron 相关的专利（医药）

登录后查看更多信息

项与 Orforglipron 相关的文献（医药）

2025-04-01·DIABETES OBESITY & METABOLISM

Comparison of the efficacy and safety of GLP‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis

Review

作者: Jiang, Linlin ; Zhao, Xuefei ; Zhang, YueHong ; Sun, WenJie ; Lian, Fengmei ; Sun, Yuting ; Gao, Qing ; Kang, Xiaomin ; Wen, Zhige ; An, Xuedong ; Duan, LiYun ; Ji, Hangyu

Abstract:

Objective:

This study aims to systematically evaluate and perform a systematic review and network meta‐analysis comparing the comprehensive cardiovascular protective effects of various glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), focusing on cardiovascular events and risk factors.

Methods:

We searched PubMed, Embase, Cochrane Library and Web of Science from inception to December 15, 2024. Included studies were published randomized controlled trials (RCTs) comparing GLP‐1RAs to placebo or other GLP‐1RAs. Missing data were standardized, and network meta‐analysis was performed using Stata 17.0. Study heterogeneity, publication bias and evidence quality were assessed using the Cochrane Risk of Bias tool and Confidence in Network Meta‐Analysis (CINeMA).

Results:

As of December 15, 2024, a total of 18 313 articles were retrieved. Based on the inclusion and exclusion criteria, 156 high‐quality studies were included, incorporating 144 782 patients and 14 different GLP‐1RAs. The network meta‐analysis demonstrated low heterogeneity, ensuring the reliability of the results. Comprehensive analysis revealed the following: Efpeglenatide was the most effective in reducing major adverse cardiovascular events. Oral semaglutide shows more significant advantages in reducing all‐cause mortality and cardiovascular mortality. Orforglipron excelled in glycaemic control and weight reduction. SC‐Semaglutide showed the greatest efficacy in lowering both systolic blood pressure and diastolic blood pressure, Liraglutide showed the greatest efficacy in lowering total cholesterol, Noiiglutide in triglycerides and Taspoglutide in low‐density lipoprotein cholesterol, but no GLP‐1RAs in high‐density lipoprotein cholesterol. GLP‐1RAs did not significantly increase the incidence of adverse events, but Orforglipron and Taspoglutide significantly increased the incidence of gastrointestinal adverse events compared with placebo.

Conclusion:

This study compared the cardiovascular benefits of different GLP‐1RAs, including reductions in cardiovascular events and improvements in multiple cardiovascular risk factors. However, due to limitations in the quantity and quality of the included studies, the conclusions should be interpreted with caution. Future large‐scale, high‐quality clinical trials are needed to validate these findings and further optimize comprehensive cardiovascular management strategies for patients.

2025-03-01·Obesity Pillars

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

Article

作者: Xu, Ling ; Li, Lujin ; Ren, Jiyuan ; Lv, Yinghua ; Zheng, Qingshan ; Yang, Juan ; Huang, Jihan ; Feng, Yulin ; Guo, Haoyang ; Wang, Yexuan

Aim:

Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical trials of GLP-1/GIP/glucagon(GCG) triple agonists are ongoing. This study compared the efficacy and safety profiles of different GLP-1 receptor agonists (GLP-1RAs) for weight reduction and explored the related influencing factors, providing quantitative information for the development of GLP-1RAs and their clinical use.

Methods:

This systematic review of public databases included placebo-controlled randomized clinical trials of GLP-1RAs. Time-course, dose-response, and covariate models were used to describe the efficacy characteristics and influencing factors of different GLP-1RAs. Subgroup analyses were performed to explore efficacy differences in receptor specificity. Meta-analyses compared the incidence of adverse event and dropout rates among different GLP-1RAs.

Results:

Fifty-five studies involving 16,269 participants and 12 GLP-1RAs were included. Six drugs showed significant dose-response relationships. The maximum weight reduction effect ranged from 4.25 kg (Liraglutide) to 22.6 kg (Retatrutide). Reported onset times ranged from 6.4 weeks (Orforglipron) to 19.5 weeks (Tirzepatide). At 52 weeks, weight reduction effects were 7.03 kg, 11.07 kg, and 24.15 kg for mono-agonists, dual-agonists, and tri-agonists, respectively. There was a significant negative correlation in the exponential pattern between age and weight reduction effect, whereas baseline weight and BMI had no significant impact. Common adverse events of GLP-1RAs, reported in the literature include nausea, vomiting, diarrhea, and constipation, with a significantly higher incidence of nausea than that of placebo.

Conclusions:

This study provides a quantitative evaluation of the efficacy and safety of GLP-1RAs and offers valuable insights into the assessment of new drugs for weight reduction.

2025-01-01·PHARMACOLOGICAL REVIEWS

Emerging pharmacotherapies for obesity: A systematic review

Review

作者: Al Rifai, Jana ; Valenzuela-Vallejo, Laura ; Rhayem, Caline ; Kokkorakis, Michail ; Mantzoros, Christos S ; Mantzoros, Christos S. ; Chakhtoura, Marlene ; Ghezzawi, Malak

The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024). We identified 53 phase 3 and phase 2 trials, with 36 emerging antiobesity drugs or combinations thereof and 4 withdrawn or terminated trials. Oral semaglutide 50 mg is the only medication that has completed a phase 3 trial. There are 14 ongoing phase 3 trials on glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (ecnoglutide, orforglipron, and TG103), GLP-1 RA/amylin agonist (CagriSema), GLP-1/glucagon RAs (mazdutide and survodutide), GLP-1/glucose-dependent insulinotropic polypeptide and glucagon RA (retatrutide), dapagliflozin, and the combination sibutramine/topiramate. Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%. Almost half of the drugs undergoing phase 2 trials are incretin analogs. The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs. Data on mortality and obesity-related complications, such as cardio-renal-metabolic events, are needed. Moreover, long-term follow-up data on the safety and efficacy of weight maintenance with novel obesity pharmacotherapies, along with studies focused on underrepresented populations, cost-effectiveness assessments, and drug availability, are needed to bridge the care gap for patients with obesity. SIGNIFICANCE STATEMENT: Obesity is the epidemic of the 21st century. Except for the newer injectable medications, drugs with suboptimal efficacy have been available in the clinician's armamentarium for weight management. However, emerging alternatives of novel agents and combinations populate the current obesity therapeutic pipeline. This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.

337

项与 Orforglipron 相关的新闻（医药）

2025-05-09

·PRNewswire

April Recap: 15 Top Health Press Releases

A roundup of the most newsworthy healthcare press releases from PR Newswire, including Eli Lilly's GLP-1 medication study results and business updates from Crunch Fitness and Regulus Therapeutics. NEW YORK, May 9, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends, here's a recap of some of the past month's most read- and engaged-with stories. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Monthly Health Press Release Roundup, April 2025. Photos provided by Ro, Garmin International, Inc. and Visit Myrtle Beach. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial "As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world," said David A. Ricks, Lilly chair and CEO. The Elizabeth Taylor AIDS Foundation Issues Emergency Grant Cycle to Address Forthcoming Gap Funding Providing financial resources to organizations in need, the initiative will be aimed at ensuring that critical, wrap-around health services for HIV treatment & prevention and programs focused on Transgender communities can continue to operate into the near future. Crunch Fitness Announces Strategic Investment from Leonard Green & Partners Under the terms of the agreement, LGP will acquire a majority interest in Crunch Fitness from TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG, and Crunch's minority shareholders. Novo Nordisk warns consumers about counterfeit Ozempic® (semaglutide) injection 1 mg in the US Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the US. The US Food and Drug Administration (FDA) has also updated its website with information about these counterfeit versions of Ozempic. IMDELLTRA® Demonstrated Superior Overall Survival in Small Cell Lung Cancer IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy. Jay Bradner, M.D., executive vice president, Research and Development, at Amgen, commented on the "overwhelming clinical benefit" stating the results "affirm IMDELLTRA as standard of care." Infant Immunization Week: Protecting Our Youngest Against Measles and More As National Infant Immunization Week arrives, Fidelis Care, along with other health experts and The Centers for Disease Control and Prevention (CDC), urge parents to ensure their children receive timely vaccinations, including the measles-mumps-rubella (MMR) vaccine, to safeguard their health and prevent the spread of infectious diseases. Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System OTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach. H.I.G. Capital Completes Acquisition of GetixHealth GetixHealth provides leading revenue cycle management (RCM) solutions to healthcare providers, featuring a comprehensive suite of services that includes patient responsibility management, eligibility and enrollment, third-party claims resolution, patient access, and insurance billing. SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine. Breakthrough Prize Announces 2025 Laureates in Life Sciences, Fundamental Physics, and Mathematics "This year's Breakthrough Prize laureates have made amazing strides – including treatments for major diseases affecting millions of people worldwide – showing once again the transformative power of curiosity-driven basic science," said Priscilla Chan and Mark Zuckerberg. Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain Ginkgo Bioworks and partners were awarded a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems. Kaiser Permanente Debuts Largest Hospital-based Renewable Microgrid in U.S. With 2MW of solar generation and 9MWh of battery storage, the system supports California's clean energy transition, reduces emissions, and saves money while boosting backup generation with renewable power. The Revival of the Ice Bucket Challenge Supports and Highlights the Critical Need for Mental Health Awareness and Discussions: The new viral sensation Takes Over Instagram Quickly Raising Thousands to Benefit the Work of Active Minds More than a decade after the original Ice Bucket Challenge captured global attention in support of the fight against ALS, The University of South Carolina's MIND club (Mental Illness Needs Discussion) has launched a bold, reimagined Ice Bucket Challenge focused on mental health. As part of their campaign, participants are encouraged to donate to Active Minds, the nation's leading nonprofit organization mobilizing youth and young adults to transform mental health norms. Meet vívoactive 6, the latest health and fitness smartwatch from Garmin vívoactive 6 includes Garmin's suite of popular fitness, wellness and smart features, plus an even brighter AMOLED display and up to 11 days of battery life. Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG Novartis will acquire Regulus for $7.00 per share in cash, with the potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion For more news like this, check out all of the latest health-related releases from PR Newswire. Trending Topics Among the health news that was distributed in April, the PR Newswire team was able to spot several larger stories that highlight the trends shaping the industry. GLP-1 Accessibility: GLP-1 medications maintained their position as healthcare's dominant topic, with April announcements focusing on expanding legitimate access while combating counterfeit products. Novo Nordisk secured two significant victories: successfully blocking unauthorized compounded versions of Wegovy® and Ozempic® while simultaneously expanding patient access through strategic telehealth partnerships. Manufacturing capacity grew with SHL Medical's new $220 million U.S. facility for autoinjectors, while innovation accelerated with Galmed's sublingual semaglutide formulation and Lilly's successful Phase 3 trial results for its oral GLP-1 medication. Consumer-focused initiatives included Ro's partnership with Charles Barkley as a GLP-1 celebrity ambassador and sPiLLRx's launch of an anonymous community platform for medication users, highlighting how companies are anticipating diverse consumer needs while working to maintain medication accessibility. National Autism Awareness Month: April brought significant attention to autism awareness and acceptance, with a notable focus on research findings and innovative support services. New CDC data, shared by The Autism Community in Action, revealed an increase in autism rates, now affecting 1 in 31 U.S. children. Organizations responded with expanded services, such as Goldfish Swim School's new adaptive lesson program and Myrtle Beach's enhanced sensory-friendly initiatives. Healthcare innovations were also prominent, with Acclaim Autism implementing Appian AI technology to reduce patient intake time by 83%, allowing children to receive care months sooner while maintaining HIPAA compliance. National Infant Immunization Week: As measles outbreaks continued to concern health officials, National Infant Immunization Week (April 21-28) generated substantial attention for the importance of childhood vaccinations. HealthTrackRx emerged as a key player, identifying over 10% of nationwide measles cases in their first week of testing. The company also partnered with the CDC to launch a rapid PCR test for H5N1, demonstrating the growing integration between private diagnostic companies and public health infrastructure to address multiple concurrent health threats. Health insurers joined the conversation with Fidelis Care urging parents to maintain vaccination schedules, emphasizing prevention as a cornerstone of pediatric health. Advocacy also expanded globally through Education Cannot Wait's campaign highlighting vaccination as an essential component of international education standards for children in crisis regions. Looking ahead: PR Newswire anticipates significant wire activity in May around Mental Health Awareness Month, National Nurses Week (May 6-12) and Skin Cancer Awareness Month. Early May announcements are expected to recognize National Women's Health Month, likely with maternal health innovations around Mother's Day. Aging and caregiving themes will also likely dominate coverage as organizations prepare for Older Americans Month with activities and resources. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期疫苗并购

2025-05-07

·EndPoints

Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live

Novo Nordisk said on Wednesday that compounding pharmacies’ production of its GLP-1 medicine semaglutide had reduced its market penetration more dramatically than it had expected — causing it to cut its full-year revenue guidance by about three percentage points. The Danish company now expects revenue growth in 2025 to come in at 13-21% at constant exchange rates, down from the 16% to 24% guided to in February. The outlook for Novo’s 2025 operating profit has been reduced by a similar degree. So how did Novo get its initial growth forecast wrong? Part of the answer is that, although semaglutide was taken off the shortage list in February , the ban on compounders producing it does not kick in until May 22 . “When we were out guiding last, we were in a situation where we were moving out of some product shortages in the US that had dampened our growth while compounding picked up,” Novo’s CEO Lars Fruergaard Jørgensen said on a call with media. “This has turned out to be larger than we had anticipated, and I think probably also many others had anticipated.” He added that it was “unprecedented” for large volumes of compounded products to be available. “We have been surprised about the magnitude of that,” he said. The new sales outlook “assumes a reduction in patients on compounded GLP-1 treatment during the second half of 2025,” Karsten Munk Knudsen, Novo’s CFO, said on the call. The rationale behind the tweaked forecast appears to have reassured investors, with Novo’s stock up around 4.5% in early trade on the Danish Stock Exchange. The company recently signed deals with Hims and other telehealth providers to offer official Wegovy instead of compounded versions. Further sales growth could come if Ozempic is approved for the liver disease known as MASH. A regulatory decision is expected in the third quarter of this year. Novo got a recent win in the shape of CVS Caremark, the largest pharmacy benefit manager in the US, choosing Wegovy as the preferred GLP-1 on its template formularies. Jørgensen said Novo did not actively pursue the formulary position, nor did it offer discounts or rebates to secure it. He attributed CVS’ choice to “the benefit of Wegovy, including the cardiovascular benefits.” He declined to say whether other PBMs might make the same decision. He said that there is pressure on PBMs to come up with solutions to the obesity crisis, “and one of the things that sometimes are used as a tactic is exclusivity.” However, he said that there is “low willingness currently by manufacturers to make bids that support exclusivity because it doesn’t really make sense in today’s environment, and this is about growing the market more than, say, cutting the current share of the established business. That’s only a fraction of the opportunity.” He said that more channels were opening up, “like the cash channel, to cater for different patient needs and also some different pricing points, more than, say, exclusive PBM contracts.” Elsewhere, the company has also been offered some reassurance on the US tariffs. “The announced tariffs currently in place do not materially change our financial outlook for 2025,” Jørgensen said. “However, a potential expansion or increase of tariffs may have a negative impact.” Pharma companies have tried to make it clear this earnings season that they are well-positioned to deal with potential sector-specific levies, a situation that is being closely watched by the industry. Jørgensen said that Novo’s once-daily oral form of semaglutide for obesity, which could become the first GLP-1 pill approved for weight loss in the US this year , will be made entirely in the US. “The manufacturing of the active pharmaceutical ingredient, bulk tablet, manufacturing and packaging of oral semaglutide 25 mg are all carried out in the United States.” All the manufacturing steps are up and running, he added. With Eli Lilly’s orforglipron nipping at oral semaglutide’s heels , Novo knows it has to make the most of its first-mover advantage. “When we submit the data to FDA, you can assume that we have what it takes to do a full launch in the US,” Jørgensen said on an analyst call Wednesday. He said that the large amount of safety data the pill has racked up — oral semaglutide has been sold for diabetes as Rybelsus since 2019 — would mean doctors trust the product. “Wegovy in a pill I think is a very attractive offering,” he said. “We’re ready to give this a big push and … show very strong commercial execution.” However, he said that the oral opportunity “will be way smaller than the injectable segment.” Separately, the company disclosed that it had dropped development of a once-weekly semaglutide pill for diabetes, citing portfolio considerations. It is not clear that there is demand for a pill with that administration schedule, and getting the dosing level right would have been tricky. Editor’s note: This article has been updated with comments from Novo Nordisk’s analyst call.

上市批准

2025-05-07

·药时空

礼来首个小分子口服GLP-1RA药物高血压症获批临床

2025年5月6日，国家药品监督管理局药品审评中心（CDE）官网显示，Eli Lilly and Company申报的Orforglipron胶囊通过临床试验默示许可，适应症为：用于治疗成人肥胖或超重患者的高血压。Orforglipron是一种在研的、每日一次的口服小分子（非肽类）胰高血糖素样肽 – 1受体激动剂（GLP-1 RA）。该药物可在全天任何时间服用，对饮食或饮水不加以限制。Orforglipron由中外制药（Chugai Pharmaceutical Co., Ltd.）发现，并于2018年授权至礼来制药开发。中外制药与礼来共同发表了这一分子的临床前药理学数据。目前，礼来正在进行orforglipron用于治疗2型糖尿病，以及用于肥胖或至少伴有一种体重相关合并症的超重成人进行体重管理的3期研究。此外，礼来还在研究orforglipron作为治疗肥胖成人的阻塞性睡眠呼吸暂停和高血压的潜在疗法。在今年4月，礼来公布了Orforglipron胶囊3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了orforglipron对比安慰剂，在饮食控制和运动基础上血糖控制仍不佳的2型糖尿病患者中的安全性和有效性。该试验在美国、中国、印度、日本和墨西哥随机分配了559名患者，按照1:1:1:1的比例接受3mg、12mg或36mg的orforglipron或安慰剂治疗。该研究的目的是证明orforglipron（3mg、12mg、36mg）在40周后相较于安慰剂组，在未接受胰岛素治疗且在首次访视前至少90天内未使用任何糖尿病药物的2型糖尿病患者中，能够显著地较基线降低糖化血红蛋白（A1C）水平。研究结果显示：各剂量组平均糖化血红蛋白（A1C）降幅为1.3%至1.6%在关键次要终点，在最高剂量下，每日一次的Orforglipron实现了平均减重7.3kg（7.9%）ACHIEVE-1研究中orforglipron的整体安全性和耐受性与注射型GLP-1药物一致关于礼来礼来制药是一家从事药品研发、生产和销售的全球领先的医药公司，致力于通过创新改善人类健康水平。礼来制药诞生于一个多世纪之前，于1876年由礼来上校在美国印第安纳州创立，公司创始人致力于生产高质量的药品以满足切实的医疗需求。资料来源：1.Pharma CMC公众号识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床3期临床2期临床结果

100 项与 Orforglipron 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高血压	临床3期	美国	Eli Lilly & Co.	2025-05-01
高血压	临床3期	中国	Eli Lilly & Co.	2025-05-01
高血压	临床3期	日本	Eli Lilly & Co.	2025-05-01
高血压	临床3期	阿根廷	Eli Lilly & Co.	2025-05-01
高血压	临床3期	捷克	Eli Lilly & Co.	2025-05-01
高血压	临床3期	德国	Eli Lilly & Co.	2025-05-01
高血压	临床3期	希腊	Eli Lilly & Co.	2025-05-01
高血压	临床3期	印度	Eli Lilly & Co.	2025-05-01
高血压	临床3期	波兰	Eli Lilly & Co.	2025-05-01
高血压	临床3期	波多黎各	Eli Lilly & Co.	2025-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05971940 (ACHIEVE-1, Biospace) 人工标引	临床3期	2型糖尿病	559	Orforglipron 3 mg	糧築膚餘鑰艱艱餘觸繭(鬱鹹窪齋繭範獵積鹹夢) = 夢觸鑰選構積糧鹹鬱淵築遞壓膚簾顧願鹹齋鏇 (蓋願淵築糧襯壓壓築鬱 ) 达到更多	积极	2025-04-17
				Orforglipron 12 mg	糧築膚餘鑰艱艱餘觸繭(鬱鹹窪齋繭範獵積鹹夢) = 築艱積觸憲鏇齋淵壓衊築遞壓膚簾顧願鹹齋鏇 (蓋願淵築糧襯壓壓築鬱 ) 达到更多
NCT05051579 (EASD2023)	临床2期	超重 \| 肥胖	272	Orforglipron (OFG) 12 mg	鑰選製壓窪繭淵淵鬱糧(觸構窪願蓋壓選壓糧築) = 築簾憲構壓鬱積壓製積製壓齋鑰憲簾艱遞衊糧 (製憲網鹽鏇觸襯襯襯蓋 ) 更多	积极	2023-10-03
				Orforglipron (OFG) 24 mg	鑰選製壓窪繭淵淵鬱糧(觸構窪願蓋壓選壓糧築) = 構顧齋繭構願遞齋蓋積製壓齋鑰憲簾艱遞衊糧 (製憲網鹽鏇觸襯襯襯蓋 ) 更多
NCT05051579 (GZGI, CTgov)	临床2期	肥胖	272	LY3502970 (24 mg LY3502970)	艱餘鑰膚淵窪鬱糧觸糧(衊獵顧構蓋窪願淵遞鏇) = 鑰憲鹽醖鏇蓋膚遞鬱壓窪選鹹獵淵淵選獵顧鹹 (膚醖衊蓋範膚鏇壓鏇夢, 0.82) 更多	-	2023-09-13
				Placebo (Placebo)	艱餘鑰膚淵窪鬱糧觸糧(衊獵顧構蓋窪願淵遞鏇) = 醖獵鏇構選廠網獵觸製窪選鹹獵淵淵選獵顧鹹 (膚醖衊蓋範膚鏇壓鏇夢, 0.81) 更多
NCT05048719 (ADA 12023 \| ADA 22023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	齋鏇簾構鹽願鹹範壓顧(窪構構衊膚構齋網醖鹹) = 構餘簾醖蓋衊艱廠遞選艱廠顧衊窪膚網醖鑰獵 (顧蓋夢製製鏇獵蓋簾艱 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	齋鏇簾構鹽願鹹範壓顧(窪構構衊膚構齋網醖鹹) = 醖築齋獵鏇繭壓範餘選艱廠顧衊窪膚網醖鑰獵 (顧蓋夢製製鏇獵蓋簾艱 ) 更多
NCT05048719 (Literature \| Pubmed \| Lancet) 人工标引	临床2期	2型糖尿病	303	orforglipron	網願範選遞糧鏇繭選獵(膚遞顧憲積積餘願顧鹹) = 廠鹹鹹憲齋選簾夢餘鹽餘構範蓋糧壓餘製積糧 (廠蓋壓衊淵醖構糧製構 ) 更多	积极	2023-06-23
				Dulaglutide	網願範選遞糧鏇繭選獵(膚遞顧憲積積餘願顧鹹) = 鏇齋遞觸膚願簾鑰範範餘構範蓋糧壓餘製積糧 (廠蓋壓衊淵醖構糧製構 ) 更多
NCT05051579 (ADA 12023 \| ADA 22023) 人工标引	临床2期	超重 \| 肥胖	272	Orforglipron 12 mg	鬱齋網積製網構憲襯範(壓鹹醖鬱鬱窪簾鬱鑰膚) = 餘鏇醖鏇鏇窪壓網廠醖選艱願鑰廠壓顧糧糧憲 (襯積製醖簾鹹衊鑰繭衊 ) 更多	积极	2023-06-23
				Orforglipron 24 mg	鬱齋網積製網構憲襯範(壓鹹醖鬱鬱窪簾鬱鑰膚) = 蓋夢範淵淵觸鹽艱鬱觸選艱願鑰廠壓顧糧糧憲 (襯積製醖簾鹹衊鑰繭衊 ) 更多
NCT05051579 (GZGI, Pubmed)	临床2期	肥胖	272	Orforglipron 12 mg	齋夢製築範構積憲簾構(願築鹽廠餘獵齋齋觸衊) = 範蓋鬱鏇鏇鹽餘繭繭構鬱獵構糧顧鹹顧窪憲顧 (醖積餘鑰醖鏇願淵積獵 )	-	2023-06-23
				Orforglipron 24 mg	齋夢製築範構積憲簾構(願築鹽廠餘獵齋齋觸衊) = 遞壓窪醖夢遞壓構襯網鬱獵構糧顧鹹顧窪憲顧 (醖積餘鑰醖鏇願淵積獵 )
NCT05110794 (ADA 12023 \| ADA 22023) 人工标引	临床1期	-	46	Orforglipron 3mg (fasted)	鏇築夢壓淵鹽鏇壓夢膚(鹹願製選餘窪網構膚淵) = 顧願鬱窪蓋淵鹽艱範選壓壓糧壓膚艱製廠醖願 (鏇鬱遞糧窪糧網膚網製 ) 更多	积极	2023-06-20
				Orforglipron 3mg (fed)	鏇築夢壓淵鹽鏇壓夢膚(鹹願製選餘窪網構膚淵) = 願廠糧壓窪夢構願製憲壓壓糧壓膚艱製廠醖願 (鏇鬱遞糧窪糧網膚網製 ) 更多
NCT04426474 (NEWS) 人工标引	临床1期	2型糖尿病	68	LY3502970	夢齋糧淵獵艱網廠網積(憲壓齋簾膚糧齋衊襯選) = 遞醖壓鬱衊壓廠選顧憲蓋鏇鹽鏇鑰壓繭製壓衊 (獵淵廠選獵築觸積餘衊 ) 更多	积极	2022-10-13
				Placebo	夢積構鑰範醖選鏇觸範(顧範齋觸繭選築窪鹹鏇) = 簾網顧鏇繭夢襯艱窪糧願壓廠鬱觸範糧構淵鹹 (廠築遞蓋網淵構獵鏇鹽 ) 更多
NCT04426474 (EASD2022)	临床1期	2型糖尿病 HbA1c	51	LY3502970	鬱鑰觸鹽艱醖餘齋蓋鏇(願鑰鹽鑰醖繭鬱廠夢餘) = One patient reported 2 severe gastrointestinal events (1 each of nausea and vomiting); all other events were mild or moderate 願網窪選齋簾夢齋製窪 (鹽選夢齋糧糧製網餘構 )	积极	2022-09-20
				Placebo